THE STUFF THAT human health care LEADERS ARE MADE OF

Ivan Cheung concurrently serves as Chairman and CEO of Eisai Inc. in the United States, as well as Global Alzheimer’s Disease Officer and Senior Corporate Officer for Eisai Co., Ltd. in Japan, the parent company of Eisai Inc. He is responsible for the strategic direction of the company in North America, which is the largest commercial region for Eisai globally. Mr. Cheung provides management oversight to all of Eisai's operating companies in the United States and Canada, including fully integrated commercial and medical organizations specializing in oncology and neurology, as well as multiple research and development facilities. He is also responsible for Eisai’s global end-to-end strategy and activities from new product development and regulatory affairs to brand commercialization and value/access to deliver breakthrough disease-modifying therapies and ecosystem solutions to people living with Alzheimer’s disease and related brain health conditions.

Since joining Eisai Co., Ltd. in 2005, Ivan has held positions of rising responsibility across corporate planning and strategy, corporate finance, talent management, global R&D, the U.S. pharmaceuticals business, the Japan consumer healthcare business, the global oncology business, and the global neurology business. Prior to joining Eisai, he was with the Global Health Practice at Booz Allen Hamilton, where he provided strategy and operations consulting to biopharmaceutical and healthcare clients in the U.S., Europe, and Asia.

Ivan received his MBA from Harvard Business School, and earned a Bachelor of Science degree in Civil/Environmental Engineering with a double major in Economics from Duke University. He is a Board member of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO).

Lynn D. Kramer, MD, FAAN, is Chief Clinical Officer, ADBH (Alzheimer’s Disease & Brain Health) at Eisai and a member of the Eisai Company Ltd. Executive Committee. In these roles, he oversees the product creation cycle including clinical introduction, and regulatory approval of innovative projects in the neuroscience and general medicine area globally. He recently received the 2022 Epilepsy Foundation Lifetime Accelerator Award.

Dr. Kramer, who has been with Eisai since 2007, started as the Executive Vice President of Global Clinical Research, and was soon promoted to the additional role of Chief Operating Officer of Eisai Medical Research. In early 2009, he was named President of the Scientific and Operational Clinical Support Core Function Unit (SOCS CFU) and President of the Neuroscience, Product Creation Unit.

He was named Chief Clinical Officer and a member of the Executive Committee, Eisai Company, Ltd. in 2012. In addition to those roles Dr. Kramer was named Chief Medical Officer of the Neuroscience Business Group in April 2016.

Prior to joining Eisai, Dr. Kramer oversaw clinical development, pharmacovigilance, drug safety and medical affairs for PAR Pharmaceutical, Inc. Earlier in his career he held senior positions in drug development such overseeing clinical development and clinical operations at Purdue Pharmaceuticals, was Vice President Clinical Research and Head of the Therapeutic Area Strategy Team at Novartis, and Vice President Clinical Research at the R.W. Johnson Pharmaceutical Research Institute.

Dr. Kramer is a Fellow of the American Board of Psychiatry and Neurology (1987) and the Philadelphia College of Physicians (1987). He previously served as the industry representative on the Peripheral and Central Nervous System Drugs Advisory Committee of the Food and Drug Administration (FDA) and on the Board of Directors at American Society for Experimental Neuro Therapeutics (ASENT). He currently is a member of the Pharma R & D Leadership Forum.

Dr. Kramer received his MD from Hahnemann Medical College. He completed his internship in internal medicine at the University of California at Irvine, and his residency in neurology at the University of Virginia. He has been Co-PI on several NIH grants: Clinical and Epidemiologic Studies of Human Epilepsies, Pharmacologic Prophylaxis of Post-Traumatic Epilepsy, and had a Master Agreement Evaluation of Investigational Antiepileptic Drugs prior to his move into industry. He also holds a Bachelor of Arts degree from Lycoming College, where he since had served on the Executive Committee Board of Trustees.

Dr. Owa is responsible for all discovery research and oversight of clinical development for the company’s oncology business.

Since joining Eisai as a scientist in the Cancer Research Division in 1991, Dr. Owa has assumed positions of increasing responsibility within the R&D operations. He specializes in anticancer research, including drug discovery and the development of sulfonamide anticancer agents, as well as target and biomarker identification of novel anticancer small molecules.

Dr. Owa received his Ph.D. in Organic Chemistry, Medicinal Chemistry and Cancer Chemistry from the University of Tokyo, with a focus on chemistry and biology of naturally-occurring and manmade bleomycins. In addition, he completed a two-year, post-doctoral fellowship in the Department of Chemistry and Chemical Biology at Harvard University.

Alexander Scott oversees all the functional departments of the company’s regional corporate services operations, including Advocacy, Compliance, Corporate Communications, Legal, Finance, Human Resources, Internal Audit, Information Technology and Product Safety. Alex is a Corporate Officer for Eisai Co., Ltd. He also serves as a trustee of the Eisai USA Foundation, the company’s philanthropic arm and as a member of the America's Executive Committee.

Since joining Eisai in 1992, Alex has helped craft the company’s U.S. globalization strategy and establish a commercial infrastructure through a variety of roles in Commercial Planning, Corporate Strategy, Business Development and Alliance Management. He has negotiated global alliances with a number of companies and played a key role in establishing business collaborations with more than 25 pharmaceutical companies. He also managed Eisai’s acquisitions of MGI PHARMA, INC. and Morphotek, Inc.

Alex holds a Bachelor of Arts in Government from Wesleyan University and a Master of Business Administration degree from Duke University. He is a member of the Licensing Executives Society, and serves as Treasurer and a Board Member of Gilda’s Club New York City.

With close to 30 years of experience in the pharmaceutical industry, Paul Hawthorne leads the Commercial, Medical Affairs and Market Access organizations for Eisai U.S. and Canada Oncology and Neurology portfolios. Paul and his teams are responsible for the development and implementation of our commercialization, data generation, data dissemination and access strategies that enable Eisai to fulfill its PURPOSE, our human health care (hhc) mission. Paul also serves as a member of the Americas Executive Committee.

In April 2016, Paul joined Eisai with the initial goal of creating and driving commercial strategies for the company’s Neurology portfolio, before being promoted to Chief Commercial Officer in January 2019 and then to his current role in December 2019.

Prior to Eisai, he spent 25 years with Sanofi, where he held senior leadership positions of increasing responsibility across all therapeutic areas.

Paul holds a Master of Business Administration in Marketing from LaSalle University. He earned his undergraduate degree from the University of Pittsburgh.

Yasutaka Yoshida is responsible for evaluating, managing and executing the strategic initiatives and market opportunities that support Eisai’s short-term and long-term planning and strategies, including operational investments, capital expansions, strategic alliances and partnerships, acquisitions and divestitures.

Mr. Yoshida, who joined Eisai in 2004 as a Medical Sales Representative, has held a variety of diverse roles of increasing responsibility during his tenure with the company. Prior to being appointed to his current role in July 2020, Mr. Yoshida spent two years working in the company’s Executive Office in Japan. In June 2019, he was promoted to Senior Director of the CEO Office, a role in which he directly supported the company’s global CEO, Dr. Haruo Naito. He has relocated to the company’s U.S. headquarters in Nutley, N.J. Before working in the Executive Office, he served two years as Associate Director of the Corporate Planning and Strategy Department, acting as the liaison between the Americas region and the global headquarters to assist in the development of the company’s strategy and financial planning. Earlier in his career, Mr. Yoshida spent four years as Manager of the Government Affairs Department, in which he worked with the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) and was a management member on Japan Pricing Policy. He also spent two years as Associate Manager in the Human Resources Department, and served two years as Associate Manager at the Japan Business Headquarters after his promotion from a Medical Sales Representative.

Mr. Yoshida holds of Bachelor of Law degree from Kobe University, and an English Language degree from the Kansai Gaidai University in Japan.

Neriman Botas serves as Executive Vice President, Human Resources. In this role, she works with Eisai's business leaders to identify priorities, align resources and cultivate a culture that enables all employees to thrive at the company. Neriman is a member of the Americas Executive Committee, as well as a trustee of the Eisai USA Foundation, the company’s philanthropic arm.

Since joining the company in 2004, Neriman has led the Human Resources organization in the design and deployment of progressive talent management practices that promote growth, accountability and empowerment. Prior to joining Eisai, Neriman spent 19 years at Schering-Plough Corporation, where she developed her human resources career in roles spanning all business segments, including both U.S. and global responsibilities.

Neriman received her Bachelor of Arts in psychology from Douglass College of Rutgers University in New Jersey. She also completed the Executive Human Resources Development Program at Cornell University School of Industrial and Labor Relations.

Masahito Suzuki serves as Vice President and Chief Financial Officer of Eisai Inc., the U.S. subsidiary of Tokyo, Japan-based Eisai Co., Ltd. In this position, he is responsible for leading all of the functions within the Finance Team. He is also a member of the company’s Executive Committee for the Americas.

Since joining Eisai in 1989 as a medical sales representative in Japan, Mr. Suzuki has held key executive roles in a variety of areas including Accounting, Corporate Planning, Finance and Oncology Strategic Planning. After spending a decade in the company’s Corporate Planning department in Tokyo, he was promoted to Senior Vice President of the Corporate Planning operations in the EMEA. Mr. Suzuki later returned to Japan to serve as the Head of the Oncology Business Group’s Strategy Department Planning Group. In October 2019, he was named Head of Accounting & Tax at Eisai Co., Ltd., where he led the team responsible for consolidated accounting. In January 2020, he was appointed Deputy Chief Financial Officer of Eisai Inc., and was promoted to his current role in April 2022.

Mr. Suzuki received his Master of Business Administration (MBA) from the Keio Business School in Tokyo. He earned his Bachelor of Commerce degree from Keio University in Tokyo.

Vincent Andrews leads Eisai's Legal Department and the Ethics & Compliance Department. Vince provides strategic executive oversight on Legal Matters, the Corporate Compliance Program and manages day-to-day Legal and Compliance operations, as well as Product Security. Over the past 16 plus years at Eisai, Vince has led or overseen several key areas for Legal‚ including Life Sciences Transactions‚ Alliance Management, Intellectual Property, and Eisai's litigation and investigations. Vince serves a member of the Americas Executive Committee, the Global Risk Management Committee and the Global Product Security Committee.

Prior to joining Eisai‚ Vince served as Assistant General Counsel to Eyetech Pharmaceuticals‚ a successful biotech start-up‚ and as Associate General Counsel to MIM Corporation in Elmsford‚ NY‚ a publicly-traded specialty pharmaceutical distributor and pharmaceutical benefit manager. In addition‚ Vince spent over five years at Schulte Roth & Zabel, advising private and public companies on corporate transactions‚ securities issuances and filings and general corporate matters.

Vince received his Juris Doctor degree from the Northeastern University School of Law. He earned his Bachelor of Arts degree in Political Science from Binghamton University.

Teresa Cronin serves as Vice President of Corporate Communications and Patient Advocacy at Eisai Inc. In this role, she is responsible for cultivating and maintaining Eisai’s corporate reputation through strategic communications and patient advocacy activities. She also serves as a member of the company’s Executive Committee for the Americas, and represents Eisai on multiple Corporate Councils.

Ms. Cronin, who has 20 years of experience as a marketer and public relations professional in the branded pharmaceutical and consumer health care markets, most recently served as Executive Director of Corporate Advocacy. In this position, she led the implementation of strategies with the objective of building and maintaining strong relationships with patient and professional organizations to advocate, enhance and promote initiatives that support Eisai’s human health care (hhc) mission. She was also responsible for the development of disease awareness campaigns with patient advocacy organizations that aim to address unmet patient needs within the company’s therapeutic areas of focus.

Upon joining Eisai in 2012 as Associate Director of Public Relations, Ms. Cronin led the strategic and tactical implementation of several programs to support Eisai’s oncology and neurology franchises. She also served as the hhc mission administrator for the Americas region from 2012-2016, in which she and her team were responsible for the creation of over 500 initiatives that enable employees to have direct interactions with patients. Through these events, the company believes employees can develop a much better understanding of patients, and thus bring these learnings back to their jobs. Ms. Cronin was promoted to Director of Corporate Advocacy in 2016.

Programs developed at Eisai under Ms. Cronin’s leadership include Magnolia™, a patient advocacy program designed to give patients living with cancer a way to address their challenges. The first initiative under Magnolia™, Magnolia Meals at Home™ provides free meals to patients and families living with breast and thyroid cancer. Magnolia™ has been expanded to include Meal Train Sponsored By Magnolia^®, an online calendar that aims to optimize the impact of meal delivery to patients and families living with breast cancer, as well as Magnolia Paws for Compassion^®, which increases access to animal assistance and the benefits that these animals can provide to those coping with illness. Other initiatives created by Ms. Cronin include #ThisisMBC, Teens for Pink, Myths and Truths about Thyroid Cancer™, Time to Talk CINV™ and My Healthy™.

Prior to joining Eisai, Ms. Cronin spent seven years at GSW Worldwide, an advertising agency that specializes in launching pharmaceutical brands in vaccines, epilepsy, women’s health and dental care.

Ms. Cronin earned her Bachelor’s Degree from Iona College in Business Management & Marketing.

Rene Rancourt is responsible for leading the information technology function for Eisai’s Americas region, and developing the strategy for IT functions, including systems design and analysis, applications and systems programming, database management, and data processing operations.

Having worked at Sanofi in France and in different capacities in the United States, Rene’s depth of knowledge and 20+ years of experience is showcased by the variety of roles he has held including project management, solution architecture, system integration, infrastructure and operations, and data analytics. In addition to his IT expertise, Rene has also held business leadership positions, including Clinical transformational program leader, R&D site director and Clinical Supply Chain Quality head. Known for his cost-saving and business oriented technological solutions, innovative ideas and ability to drive growth and transform, Rene is an effective change agent.

After leaving Sanofi, Rene served as the interim CIO for Brancher Inks and co-founded a start-up as the CTO.

Most recently, he was the Global Head of IT at Ichnos Sciences, a biotech company focused on immuno-oncology. While at Ichnos, he built an IT strategy supporting the company’s shift from start-up to growth mode.

Rene has a Master of Science Degree in Computer Science, Thermo-Dynamics from Ecole Nationale Superieure des Mines de Nancy, in France. He holds various certifications, including Amazon Web Services (AWS) Certified Cloud Practitioner, Microsoft Azure Fundamentals and Machine Learning from Stanford.